EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Reevaluating the Imiquimod Model: A Barrier to Translational Progress in Psoriasis

Catherine C Smith, Ian M Zwerner, Johann E Gudjonsson, Nicole L Ward

Journal of Investigative Dermatology · 2026-02 · 146 (2) · 322-327

DOI: 10.1016/j.jid.2025.09.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Investigative Dermatology, 2026-02. Verfasst von Catherine C Smith und 3 weiteren Autor:innen. Beteiligte Einrichtung: College of Medicine, The University of Tennessee Health Science Center, Memphis, Tennessee, USA; Department of Dermatology, School of Medicine, Vande…. Hauptthemen laut MEDLINE: Psoriasis, Imiquimod, Disease Models, Animal, Translational Research, Biomedical. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, NIAID NIH HHS, University of Michigan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Once hailed as a breakthrough in psoriasis research, the imiquimod (IMQ) mouse model is now overused, inconsistently applied, and increasingly disconnected from human disease. Nearly a decade after our initial critique, the field remains reliant on a tool that models acute, innate inflammation rather than chronic, adaptive immunity. In this paper, we revisit the limitations of the IMQ model, highlighting methodological drift, poor transcriptomic overlap with psoriasis, and the illusion of mechanistic discovery. We argue that progress in psoriasis research now depends on moving beyond this model toward more faithful systems that reflect the complexity of human disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisImiquimodDisease Models, AnimalTranslational Research, BiomedicalAminoquinolinesAnimalsHumansMiceImmunity, Innate

Stichwörter der Autor:innen

IL-23/IL-17Mouse modelPreclinical drug testingPsoriasis mouseSkin inflammation

Substanzen

ImiquimodAminoquinolines

Autor:innen und Institutionen

  • College of Medicine, The University of Tennessee Health Science Center, Memphis, Tennessee, USA; Department of Dermatology, School of Medicine, Vanderbilt University, Nashville, Tennessee, USA; Vanderbilt University Med…
  • Department of Dermatology, School of Medicine, Vanderbilt University, Nashville, Tennessee, USA; Vanderbilt University Medical Center, Nashville, Tennessee, USA; Montgomery Bell Academy, Nashville, Tennessee, USA.
  • Department of Dermatology, University of Michigan, Ann Arbor, Michigan, USA; Taubman Medical Research Institute, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Department of Dermatology, School of Medicine, Vanderbilt University, Nashville, Tennessee, USA; Vanderbilt University Medical Center, Nashville, Tennessee, USA; Vanderbilt Institute for Infection, Immunology, and Infla…

Förderung

  • NIAMS NIH HHS
  • NIAID NIH HHS
  • University of Michigan
  • VANDERBILT UNIVERSITY MEDICAL CENTER
  • National Psoriasis Foundation
  • National Institutes of Health

Zitieren

APA

Smith, C. C., Zwerner, I. M., Gudjonsson, J. E., & Ward, N. L. (2026). Reevaluating the Imiquimod Model: A Barrier to Translational Progress in Psoriasis. Journal of Investigative Dermatology, 146(2), 322-327. https://doi.org/10.1016/j.jid.2025.09.005

Vancouver

Smith CC, Zwerner IM, Gudjonsson JE, Ward NL. Reevaluating the Imiquimod Model: A Barrier to Translational Progress in Psoriasis. Journal of Investigative Dermatology. 2026;146(2):322-327. doi:10.1016/j.jid.2025.09.005

BibTeX
@article{Smith2026,
  author = {Smith, Catherine C and Zwerner, Ian M and Gudjonsson, Johann E and Ward, Nicole L},
  title = {Reevaluating the Imiquimod Model: A Barrier to Translational Progress in Psoriasis},
  journal = {Journal of Investigative Dermatology},
  year = {2026},
  volume = {146},
  number = {2},
  pages = {322--327},
  doi = {10.1016/j.jid.2025.09.005}
}
Kostenlos starten →